Ischemia-modified albumin predicts mortality in ESRD

Area of Science:

• Cardiology
• Nephrology
• Biomarker Research

Background:

• End-stage renal disease (ESRD) patients face high mortality risks.
• Identifying reliable mortality predictors in ESRD is crucial for patient management.
• Ischemia-modified albumin (IMA) is a potential biomarker for oxidative stress.

Purpose of the Study:

• To investigate if ischemia-modified albumin (IMA) levels predict mortality in ESRD patients.
• To characterize patients with elevated IMA levels.
• To compare IMA with cardiac troponin T (cTnT) for mortality prediction.

Main Methods:

• Prospective observational study of 114 renal transplantation candidates.
• Coronary angiography and dobutamine stress echocardiography were performed.
• Total mortality was the primary end point, with a follow-up of 2.25 years.

Main Results:

• IMA and cardiac troponin T (cTnT) levels both predicted mortality.
• IMA levels ≥ 95 KU/L showed 76% sensitivity and 74% specificity for mortality.
• Multivariate analysis identified positive dobutamine stress echocardiography, combined elevated IMA/cTnT, and E/Ea ratio as independent predictors.

Conclusions:

• IMA levels are a significant predictor of mortality in ESRD patients.
• Elevated IMA is associated with larger left ventricular (LV) size, reduced LV systolic function, and increased LV filling pressures.
• IMA serves as a valuable prognostic marker in this high-risk population.